NXT007 Clinical Trials (2026): 4 Studies for Hemophilia A & Healthy Male Participants
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 NXT007 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Hemophilia A & Healthy Male Participants) and 594 total planned enrollment. 2 Phase 3 NXT007 trials are listed. 3 NXT007 clinical trials are actively recruiting at 6 U.S. sites across 4 states. Most recent activity: NCT07416604 (Jan 2032).
Where to Participate: All NXT007 Trial Sites in the U.S. (6 sites across 4 states)
Every actively recruiting NXT007trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Center for Inherited Blood Disorders | Orange92868 | NCT07416604 | Map |
| CA | UC Davis Cancer Center | Sacramento95817 | NCT05987449 | Map |
| IN | Indiana Hemophilia & Thrombosis center | Indianapolis46260 | NCT05987449 | Map |
| IN | Innovative Hematology, Inc. | Indianapolis46260 | NCT07416604 | Map |
| IA | University of Iowa Hospitals and Clnics Dept of Pediatrics | Iowa City52242 | NCT05987449 | Map |
| WA | Washington Center for Bleeding Disorders | Seattle98101-3932 | NCT07416604 | Map |
NXT007 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 | |
| P3 | 2 | 2 |
Recruiting NXT007 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07416604 | ZEBRHA 2A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A | P3 | Hemophilia A | 360 | Apr 2026 |
| NCT07416526 | ZEBRHA 1A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | P3 | Hemophilia A | 126 | May 2026 |
| NCT05987449 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A | P1/P2 | Hemophilia A | 60 | Sep 2023 |
NXT007 clinical trials by indication
Hemophilia A (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07416604 | ZEBRHA 2 | P3 | recruiting | A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A |
| NCT07416526 | ZEBRHA 1 | P3 | recruiting | A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A |
| NCT05987449 | — | P1/P2 | recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A |
Healthy Male Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06189508 | — | P1 | completed | A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants |
NXT007 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ZEBRHA 2 | NCT07416604 | P3 | recruiting | Hemophilia A | 360 | — |
| ZEBRHA 1 | NCT07416526 | P3 | recruiting | Hemophilia A | 126 | — |
All NXT007 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07416604 | ZEBRHA 2 | A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A | P3 | recruiting | 360 | Hoffmann-La Roche | Apr 2026 |
| NCT07416526 | ZEBRHA 1 | A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | P3 | recruiting | 126 | Hoffmann-La Roche | May 2026 |
| NCT05987449 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A | P1/P2 | recruiting | 60 | Hoffmann-La Roche | Sep 2023 | |
| NCT06189508 | A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants | P1 | completed | 48 | Hoffmann-La Roche | Feb 2024 |
NXT007 clinical trials: frequently asked questions
- How many NXT007 clinical trials are there?
- 4 NXT007 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 1 is marked completed.
- Are NXT007 clinical trials recruiting in 2026?
- Yes — 3 NXT007 trials are actively recruiting in 2026, with 6 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is NXT007 being studied for?
- NXT007 is being studied for Hemophilia A, Healthy Male Participants. The trials are grouped by indication on this page.
- What phase is NXT007 in?
- NXT007 clinical trials span 2 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors NXT007 clinical trials?
- The lead sponsor across the most NXT007 trials is Hoffmann-La Roche. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming NXT007as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: